-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Reiterates Outperform on Ovid Therapeutics, Maintains $7 Price Target

Benzinga·04/15/2026 12:27:21
Listen to the news
Wedbush analyst Laura Chico reiterates Ovid Therapeutics (NASDAQ:OVID) with a Outperform and maintains $7 price target.